The FDA approved Zepbound (tirzepatide) to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, alongside a reduced-calorie diet and increased physical activity [4]. The evidence below applies to this drug and population.
What the trials found at 52 weeks
The two SURMOUNT-OSA trials compared tirzepatide with placebo. Trial 1 enrolled people who were unable or unwilling to use positive airway pressure (PAP). Trial 2 enrolled people already on PAP. They continued PAP during the trial, with a seven-day pause before assessment of the primary outcome. Participants in both groups received diet and physical activity counseling [1] [4].
The apnea-hypopnea index (AHI) counts episodes of stopped or reduced breathing per hour of sleep. Mean baseline AHI across the treatment and placebo groups was 51.5 in Trial 1 and 49.5 in Trial 2. At week 52, estimated AHI changes in Trial 1 were −25.3 with tirzepatide and −5.3 with placebo, a difference of −20.0 events per hour (95% confidence interval −25.8 to −14.2). In Trial 2, changes were −29.3 and −5.5, a difference of −23.8 (−29.6 to −17.9). Both comparisons had P < 0.001 [1].
In a separate analysis, a UK study of new sleep apnea diagnoses found no clear reduction in incident OSA among adults with obesity and type 2 diabetes who started a GLP-1 receptor agonist compared with those who started a DPP-4 inhibitor. That study asked about prevention, while SURMOUNT-OSA measured changes in adults who already had OSA [2].
Dose and coverage
The trials began at 2.5 mg weekly and took up to 20 weeks to reach the maximum tolerated dose of 10 or 15 mg. Those are also the approved weekly maintenance doses for OSA [4]. If comparing self-pay offers, check how quoted prices change with dose before using a starting price to estimate ongoing costs.
The Medicare guide to Zepbound for OSA explains how the diagnosis, supporting records and plan rules affect coverage. Published cash prices may apply to different formulations or care packages, so check what the price includes.
Follow-up for people who use PAP
A survey of 24 European sleep centers found that PAP management and follow-up practices varied. It describes what centers reported, without measuring individual patient outcomes [3].
The American Academy of Sleep Medicine says follow-up polysomnography or home sleep apnea testing may be appropriate after a clinically significant weight change [5].